Complete financial analysis of Beam Therapeutics Inc. (BEAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beam Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Lyra Therapeutics, Inc. (LYRA) Income Statement Analysis – Financial Results
- Satudora Holdings Co.,Ltd. (3544.T) Income Statement Analysis – Financial Results
- Montrose Environmental Group, Inc. (MEG) Income Statement Analysis – Financial Results
- Alta Equipment Group Inc. (ALTG-PA) Income Statement Analysis – Financial Results
- Kurotani Corporation (3168.T) Income Statement Analysis – Financial Results
Beam Therapeutics Inc. (BEAM)
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 377.71M | 60.92M | 51.84M | 24.00K | 18.00K | 0.00 | 0.00 |
| Cost of Revenue | 437.38M | 22.58M | 16.44M | 103.18M | 5.41M | 650.00K | 11.00K |
| Gross Profit | -59.67M | 38.34M | 35.40M | -103.16M | -5.39M | -650.00K | -11.00K |
| Gross Profit Ratio | -15.80% | 62.94% | 68.29% | -429,812.50% | -29,938.89% | 0.00% | 0.00% |
| Research & Development | 437.38M | 311.59M | 387.09M | 103.18M | 54.62M | 33.87M | 5.86M |
| General & Administrative | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -71.00K | -10.04M | 378.00K |
| Operating Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Cost & Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Interest Income | 0.00 | 15.30M | 9.00K | 1.57M | 2.49M | 292.00K | 0.00 |
| Interest Expense | 0.00 | 15.30M | 9.00K | 1.57M | 187.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 20.01M | 22.58M | 16.44M | 9.47M | 5.41M | 650.00K | 11.00K |
| EBITDA | -156.47M | -324.33M | -392.47M | -128.03M | -71.65M | -45.09M | -7.99M |
| EBITDA Ratio | -41.43% | -659.03% | -799.13% | -269,270.83% | -384,644.44% | 0.00% | 0.00% |
| Operating Income | -176.49M | -338.48M | -392.47M | -132.76M | -75.15M | -45.74M | -7.88M |
| Operating Income Ratio | -46.73% | -555.61% | -757.01% | -553,166.67% | -417,522.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.32M | 78.30M | 21.83M | -61.83M | -3.17M | -71.00M | -122.00K |
| Income Before Tax | -131.16M | -260.18M | -370.64M | -194.59M | -78.33M | -116.74M | -8.00M |
| Income Before Tax Ratio | -34.73% | -427.08% | -714.91% | -810,800.00% | -435,144.44% | 0.00% | 0.00% |
| Income Tax Expense | 1.37M | 3.41M | -29.28M | 61.83M | 116.00K | -71.00M | 500.00K |
| Net Income | -132.53M | -263.59M | -341.36M | -256.42M | -78.44M | -115.26M | -8.00M |
| Net Income Ratio | -35.09% | -432.68% | -658.44% | -1,068,433.33% | -435,788.89% | 0.00% | 0.00% |
| EPS | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| EPS Diluted | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| Weighted Avg Shares Out | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
| Weighted Avg Shares Out (Dil) | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
2 gene editing stocks to keep on your 2024 watchlist
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
3 Stocks to Buy in the Booming Field of Gene Editing
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
3 Biotechs With Promising Gene Therapies in the Spotlight
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?
Source: https://incomestatements.info
Category: Stock Reports